コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ho are unlikely to benefit from prophylactic implantable cardioverter defibrillator.
2 e, 840 patients (42%) were implanted with an implantable cardioverter defibrillator.
3 ility of life-saving preventive therapy, the implantable cardioverter defibrillator.
4 icular pacemaker, and 1 has a single chamber implantable cardioverter defibrillator.
5 e can be safely managed long-term without an implantable cardioverter-defibrillator.
6 -term prognosis without the protection of an implantable cardioverter-defibrillator.
7 either documented on ECG or recorded via an implantable cardioverter-defibrillator.
8 erent implant techniques of the subcutaneous implantable cardioverter-defibrillator.
9 isk is sufficient to justify placement of an implantable cardioverter-defibrillator.
10 ttery life of approximately 3 to 7 years for implantable cardioverter-defibrillators.
11 e frequently among index-patients without an implantable cardioverter-defibrillator (10/63, 16% versu
12 med in 1,612 hospitals); 2) ICD Registry for implantable cardioverter-defibrillators (158,649 procedu
14 509 patients who had a pacemaker (58%) or an implantable cardioverter-defibrillator (42%) that was no
16 relative death risk than those receiving an implantable cardioverter-defibrillator (absolute differe
17 only 2 cardiac arrest survivors treated with implantable cardioverter-defibrillator alone but did not
18 , beta-blockers alone in 350 (58%) patients, implantable cardioverter-defibrillators alone in 25 (4%)
19 or ventricular fibrillation; and n=8 without implantable cardioverter defibrillator although with sym
20 , for the terms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic
21 45% versus 56% among patients randomized to implantable cardioverter-defibrillator and CRT with defi
22 nd impact of treatment options including the implantable cardioverter-defibrillator and heart transpl
24 published appropriate use criteria (AUC) for implantable cardioverter-defibrillators and cardiac resy
25 lipidemia, coronary artery disease severity, implantable cardioverter defibrillator, and incomplete r
26 at-risk patients who are not eligible for an implantable cardioverter defibrillator, and suggests tha
27 ejection fraction 35% or less, an automatic implantable cardioverter defibrillator, and who were ine
28 s, kidney disease, cardiac resynchronization implantable cardioverter-defibrillator, and VT storm des
29 ronic devices (CIEDs), including pacemakers, implantable cardioverter-defibrillators, and cardiac res
32 eligible for sudden death prevention with an implantable cardioverter-defibrillator are identified.
34 Multivariate analysis showed that in the implantable cardioverter defibrillator arm, each 10-mm H
35 ovariates suggested for effect modification (implantable cardioverter defibrillator at baseline, left
36 with a greater increase in RWT compared with implantable cardioverter-defibrillator at 12 months (4.6
38 F or death and CRT with defibrillator versus implantable cardioverter defibrillator benefit was asses
41 lar tachycardia, insertion of a pacemaker or implantable cardioverter-defibrillator, cardiac transpla
42 rk Heart Association HF class, and implanted implantable cardioverter defibrillator/cardiac resynchro
44 ng risk stratification of primary prevention implantable cardioverter defibrillators considering the
46 However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients w
48 mporary treatment 18 experienced appropriate implantable cardioverter-defibrillator discharges, 2 und
49 patients with dilated cardiomyopathy (DCM), implantable cardioverter-defibrillators do not increase
50 all-cause mortality, composite end point of implantable cardioverter-defibrillator efficacy (arrhyth
51 .35; 95% CI: 1.27 to 1.44), and pacemaker or implantable cardioverter-defibrillator event rate of 4.2
53 bined endpoint of cardiac death, appropriate implantable cardioverter-defibrillator firing, resuscita
54 The most frequent reason not to implant an implantable cardioverter defibrillator following WCD use
56 eceiving a cardiac resynchronization therapy implantable cardioverter defibrillator for the treatment
58 arrhythmia and implantation of an automatic implantable cardioverter-defibrillator for prevention of
59 erion for selecting patients with DCM for an implantable cardioverter-defibrillator for primary preve
60 ation of at-risk patients and utilization of implantable cardioverter-defibrillators for prevention o
61 ion of high-risk patients who benefited from implantable cardioverter-defibrillators for sudden death
62 ODS AND Patients implanted with subcutaneous implantable cardioverter-defibrillators from 2 hospitals
64 hmic therapy and the life-saving role of the implantable cardioverter-defibrillator highlight the imp
65 xercise is often avoided after receipt of an implantable cardioverter defibrillator (ICD) because of
66 previously showed a survival benefit of the implantable cardioverter defibrillator (ICD) in males wi
67 about the use of CRT in combination with an implantable cardioverter defibrillator (ICD) in patients
68 ational Cardiovascular Data Registry (NCDR), implantable cardioverter defibrillator (ICD) registry be
69 ecently, magnetic resonance (MR)-conditional implantable cardioverter defibrillator (ICD) systems hav
71 wed a significant reduction in inappropriate implantable cardioverter defibrillator (ICD) therapy in
72 and heterogeneity of LGE predict appropriate implantable cardioverter defibrillator (ICD) therapy in
74 fic level of improvement will predict future implantable cardioverter defibrillator (ICD) therapy.
75 as among patients randomized to CRT-D versus implantable cardioverter defibrillator (ICD) were compar
76 ipt of CRT with defibrillator (CRT-D) versus implantable cardioverter defibrillator (ICD), and outcom
77 he use of remote patient monitoring (RPM) of implantable cardioverter defibrillators (ICD) and all-ca
78 with defibrillator (CRT-D) compared with an implantable cardioverter-defibrillator (ICD) alone are u
79 ess of CRT with defibrillator (CRT-D) versus implantable cardioverter-defibrillator (ICD) alone in CR
81 k patients eligible for a primary prevention implantable cardioverter-defibrillator (ICD) are less li
82 ave their EF reassessed 40 days after MI for implantable cardioverter-defibrillator (ICD) candidacy.
84 through catheter ablation and ultimately an implantable cardioverter-defibrillator (ICD) for prompt
86 isk score predictive of an inadequate DSM at implantable cardioverter-defibrillator (ICD) implantatio
88 have found that primary prevention use of an implantable cardioverter-defibrillator (ICD) improves su
90 nter trials have established the role of the implantable cardioverter-defibrillator (ICD) in the trea
93 g survivors of myocardial infarction with an implantable cardioverter-defibrillator (ICD) is frequent
96 Patients with an unused or malfunctioning implantable cardioverter-defibrillator (ICD) lead may ha
97 te the impact of lead diameter and design on implantable cardioverter-defibrillator (ICD) lead surviv
98 n hospitalizations in patients randomized to implantable cardioverter-defibrillator (ICD) or ICD-CRT
99 or IIa indications for CRT-D were matched to implantable cardioverter-defibrillator (ICD) patients wi
100 ackground: Long-term nonfatal outcomes after implantable cardioverter-defibrillator (ICD) placement a
101 r rehospitalization after primary prevention implantable cardioverter-defibrillator (ICD) placement i
102 EF) is recommended before primary prevention implantable cardioverter-defibrillator (ICD) placement.
103 ricular arrhythmias (VAs) and should undergo implantable cardioverter-defibrillator (ICD) placement.
105 utaneous coronary intervention (CathPCI) and implantable cardioverter-defibrillator (ICD) registries
106 the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator (ICD) Registry ho
107 (CSD) has been shown to reduce the burden of implantable cardioverter-defibrillator (ICD) shocks in s
108 k of mortality associated with inappropriate implantable cardioverter-defibrillator (ICD) shocks is d
109 rictions for 3 to 6 months after appropriate implantable cardioverter-defibrillator (ICD) shocks, con
110 .5 tesla for patients who had a pacemaker or implantable cardioverter-defibrillator (ICD) that was "n
111 cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) therapies i
112 efit for cardiac resynchronization (CRT) and implantable cardioverter-defibrillator (ICD) therapies i
113 onal class III symptoms did not benefit from implantable cardioverter-defibrillator (ICD) therapy and
114 ecently that a long detection window reduces implantable cardioverter-defibrillator (ICD) therapy in
116 als have demonstrated improved survival with implantable cardioverter-defibrillator (ICD) therapy.
117 zation therapy with defibrillator (CRT-D) to implantable cardioverter-defibrillator (ICD) treatment i
119 tients fulfilling Class I indications for an implantable cardioverter-defibrillator (ICD) was signifi
120 ypes of devices that include the transvenous implantable cardioverter-defibrillator (ICD) with or wit
121 HF, divided into three groups: HF without an implantable cardioverter-defibrillator (ICD), HF with an
122 y an automatic external defibrillator (AED), implantable cardioverter-defibrillator (ICD), or wearabl
123 tion ECGs would predict arrhythmic events in implantable cardioverter-defibrillator (ICD)-eligible ca
129 imaging (MRI) of patients with conventional implantable cardioverter-defibrillators (ICD) is contrai
130 art failure patients with primary prevention implantable cardioverter-defibrillators (ICD) may experi
132 a current primary prevention defibrillator (implantable cardioverter-defibrillator [ICD]) population
133 any duration in patients with pacemakers and implantable cardioverter defibrillators (ICDs) and evalu
136 licting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for prima
138 at high SCD risk, prophylactic insertion of implantable cardioverter defibrillators (ICDs) reduces m
141 sequence, was evaluated in 12 patients with implantable cardioverter defibrillators (ICDs) who were
142 The study group comprised 160 patients with implantable cardioverter defibrillators (ICDs), of whom
148 ted risk for sudden cardiac death (SCD), and implantable cardioverter-defibrillators (ICDs) are the m
149 are the mainstay of therapy; when they fail, implantable cardioverter-defibrillators (ICDs) are used
150 Appropriate guideline criteria for use of implantable cardioverter-defibrillators (ICDs) do not ta
153 for each adverse HCM complication, including implantable cardioverter-defibrillators (ICDs) for sudde
157 Contemporary patterns of use and outcomes of implantable cardioverter-defibrillators (ICDs) in commun
159 most frequent complications associated with implantable cardioverter-defibrillators (ICDs) involve t
160 e how often patients with primary prevention implantable cardioverter-defibrillators (ICDs) meet guid
161 risk of atrial fibrillation in patients with implantable cardioverter-defibrillators (ICDs), but vent
162 t advances in management strategy, including implantable cardioverter-defibrillators (ICDs), heart tr
163 ufacturer-specific, strategic programming of implantable cardioverter-defibrillators (ICDs), includin
164 between 2008 and 2011 with pacemakers (PMs), implantable cardioverter-defibrillators (ICDs), or cardi
168 care in patients undergoing implantation of implantable cardioverter-defibrillators (ICDs); however,
169 retrospective cohort study of patients with implantable cardioverter-defibrillators identified from
170 rience a significant complication related to implantable cardioverter defibrillator implantation in c
171 of patients who are the best candidates for implantable cardioverter defibrillator implantation is o
172 d this observation require further study but implantable cardioverter defibrillator implantation shou
173 rdiomyopathy referred for primary prevention implantable cardioverter defibrillator implantation were
175 rgitation, incomplete revascularization, and implantable cardioverter defibrillator implantation.
176 erizes CHD and pediatric patients undergoing implantable cardioverter defibrillator implantation.
177 risk of nonsudden death who may benefit from implantable cardioverter defibrillator implantation.
178 ho did not have a preexisting indication for implantable cardioverter defibrillator implantation.
179 ed cardiac magnetic resonance imaging before implantable cardioverter-defibrillator implantation for
180 is important for the decision making before implantable cardioverter-defibrillator implantation for
181 icular arrhythmias, sudden cardiac death, or implantable cardioverter-defibrillator implantation in a
182 fter 1 month, implying that further delay of implantable cardioverter-defibrillator implantation may
183 refore, the strategy to confine prophylactic implantable cardioverter-defibrillator implantation to p
184 of DFT versus no-DFT testing at the time of implantable cardioverter-defibrillator implantation was
185 r AMI, there is no survival benefit of early implantable cardioverter-defibrillator implantation, and
186 Outcome in index-patients was modulated by implantable cardioverter-defibrillator implantation, but
187 ch to the selection of patients with DCM for implantable cardioverter-defibrillator implantation.
188 may have direct impact on the indication of implantable cardioverter-defibrillator implantation.
189 of VT), 19 of 45 patients (42.2%) underwent implantable cardioverter-defibrillators implantation.
190 rent guidelines only recommend the use of an implantable cardioverter defibrillator in patients with
191 ration (>/=120 ms) receiving either CRT-D or implantable cardioverter defibrillator in subgroups acco
192 Patients III [ADVANCE III], and Programming Implantable Cardioverter-Defibrillators in Patients with
193 Danish Study to Assess the Efficacy of ICDs [Implantable Cardioverter Defibrillators] in Patients Wit
195 the chest, nuclear procedures, and pacemaker/implantable cardioverter-defibrillator insertion and rep
196 terventions (1.0 to 2.4 per 1000), pacemaker/implantable cardioverter-defibrillator insertions (1.6 t
197 vice-related complications and inappropriate implantable cardioverter defibrillator interventions.
198 ed in 63 other high-risk patients (13%) with implantable cardioverter-defibrillator interventions for
201 Although for patients at increased risk an implantable cardioverter-defibrillator is recommended, i
203 sk in the long-term management of indwelling implantable cardioverter-defibrillator leads in young pa
204 s, 44 patients received secondary prevention implantable cardioverter-defibrillators (long QT syndrom
205 ubcutaneous implantation of the subcutaneous implantable cardioverter-defibrillator may offer procedu
206 ence of a permanent pacemaker rather than an implantable cardioverter-defibrillator (odds ratio, 3.90
207 F hospitalization or death with CRT-D versus implantable cardioverter-defibrillator only therapy, whe
209 us implantable cardioverter defibrillator or implantable cardioverter defibrillator-only in a 3:2 rat
210 Patients with persistent AF, dual-chamber implantable cardioverter defibrillator or cardiac resync
211 patients were randomly assigned to CRT plus implantable cardioverter defibrillator or implantable ca
213 tuations that may warrant implantation of an implantable cardioverter-defibrillator or cardiac resync
216 s to investigate the impact of an additional implantable cardioverter-defibrillator over CRT, accordi
217 o 26.8% (p < 0.0001); the frequency of VT in implantable cardioverter-defibrillator patients with rec
218 coronary artery bypass grafts, 2 epicardial implantable cardioverter defibrillator placement, 5 valv
220 alone, this results in approximately 130 000 implantable cardioverter defibrillator placements at a c
224 m the National Cardiovascular Data Registry, implantable cardioverter-defibrillator registry between
225 -producing course for CIEDs, pacemakers, and implantable cardioverter-defibrillators, respectively.
226 ated with early adoption of the subcutaneous implantable cardioverter defibrillator (S-ICD) in the Un
229 CM) ECG make it a challenge for subcutaneous implantable cardioverter-defibrillator (S-ICD) screening
230 recently commercially available subcutaneous implantable cardioverter-defibrillator (S-ICD) uses a co
232 2.8 [2.1-3.7]), and survivors more often had implantable cardioverter defibrillator's implanted (OR,
233 nsidering the competing risks of appropriate implantable cardioverter defibrillator shock versus mort
235 nd point including death, HT, or appropriate implantable cardioverter-defibrillator shock were assess
237 tation; n=6 with previous cardiac arrest and implantable cardioverter defibrillator shocks for ventri
238 ming with the risks of death from any cause, implantable cardioverter defibrillator shocks, and synco
243 Radiofrequency catheter ablation reduced implantable cardioverter-defibrillator shocks and VT epi
244 recurrence; the proportion of patients with implantable cardioverter-defibrillator shocks decreased
246 rphic ventricular tachycardia requiring >/=2 implantable cardioverter-defibrillator shocks occurred i
248 opriate ventricular fibrillation-terminating implantable cardioverter-defibrillator shocks, and sudde
251 Programmed settings to reduce nonessential implantable cardioverter defibrillator therapies (therap
254 ion 30%) were studied (6 month preprocedural implantable cardioverter defibrillator therapies: median
255 lated to higher risk of mortality or HF with implantable cardioverter defibrillator therapy alone.
256 Women are less likely to be referred for implantable cardioverter defibrillator therapy despite c
257 proportion of patients received appropriate implantable cardioverter defibrillator therapy during me
258 compare risk of end point events by CRT-D to implantable cardioverter defibrillator therapy in the PR
259 ation, sudden cardiac death, and appropriate implantable cardioverter defibrillator therapy was noted
260 out-of-hospital cardiac arrest, appropriate implantable cardioverter defibrillator therapy, and sudd
269 predicted to have an attenuated benefit from implantable cardioverter-defibrillator therapy (older ad
271 metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MA
272 his disease, it is also well recognized that implantable cardioverter-defibrillator therapy is associ
273 n remains challenging because the benefit of implantable cardioverter-defibrillator therapy may not b
275 t benefit from additional primary prevention implantable cardioverter-defibrillator therapy, as oppos
276 point was a composite of SCD and appropriate implantable cardioverter-defibrillator therapy, identica
277 ion of primary combined outcome (appropriate implantable cardioverter-defibrillator therapy, survived
281 THODS AND Pigs implanted with single-chamber implantable cardioverter defibrillators to record ventri
283 nts with a clinical diagnosis of CPVT and an implantable cardioverter-defibrillator underwent a basel
284 w incidence of SCD and a low rate of primary implantable cardioverter-defibrillator utilization in pa
285 pite a low rate (4.0%) of primary prevention implantable cardioverter-defibrillator utilization.
287 n men, the lower mortality with CRT-D versus implantable cardioverter defibrillator was less pronounc
290 on to such an extent that the indication for implantable cardioverter-defibrillator was no longer pre
291 therapy with defibrillator (CRT-D; CRT with implantable cardioverter-defibrillator) was associated w
292 ction </=35% referred for primary prevention implantable cardioverter defibrillator, we developed dua
295 th BrS, median age 39 years (30.3-42.3) with implantable cardioverter-defibrillator were enrolled.
298 ecome eligible for a late primary prevention implantable cardioverter-defibrillator with LVEF </=30%
299 23 patients (29%) of 78 IVF patients with an implantable cardioverter-defibrillator, with a median of
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。